Evidence map›Paper›PMID 34076348›Full record

SynthesisInternational journal of rheumatic diseases2021

Systematic review and meta-analysis on prevalence of metabolic syndrome in psoriatic arthritis, rheumatoid arthritis and psoriasis.

Aravinthan Loganathan, Narainraj Kamalaraj, Carlos El-Haddad, Kevin Pile

Registry-linked trialAbstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in International journal of rheumatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07443956 (Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis), which is not on this map. Cited by 32 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07443956 narecruitingstarted 2026, after this paper: background citation

Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis

Ran2026Enrolled45Registered outcomes5Posted comparisons0ConditionsObesity & Overweight, Psoriatic Arthritis (PsA)ArmsIxekizumab, Tirzepatide
PMID 22586165PMID 15708927PMID 17698691PMID 22562978PMID 31209855PMID 31292564PMID 33147607PMID 33423070PMID 34300360PMID 34453579PMID 36264448PMID 37667975other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Lifestyle Modification for the Management of Psoriatic Arthritis.American journal of lifestyle medicine · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Aravinthan LoganathanRheumatology Department, Campbelltown Hospital, Campbelltown, NSW, Australia.ORCID https://orcid.org/0000-0003-3576-7204
Narainraj KamalarajRheumatology Department, Campbelltown Hospital, Campbelltown, NSW, Australia.
Carlos El-HaddadRheumatology Department, Campbelltown Hospital, Campbelltown, NSW, Australia.
Kevin PileRheumatology Department, Campbelltown Hospital, Campbelltown, NSW, Australia.
Camden and Campbelltown Hospitals · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPsoriatic arthritis (PsA), rheumatoid arthritis (RA) and psoriasis (PsO) are associated with systemic inflammation and increased cardiovascular mortality and morbidity. Metabolic syndrome (MetS) is associated with systemic inflammation, and conditions associated with MetS, such as obesity, are associated with difficulty in attaining minimal disease activity (MDA) in individuals with inflammatory arthritis. This systematic review aims to determine whether there is an increased prevalence of MetS in PsA populations compared with PsO and RA populations.

methodsA systematic review was conducted to assess the prevalence of MetS in PsA, PsO, and RA populations following Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. The quality of the studies reviewed was assessed using the Joanna Briggs Institute Checklist for Prevalence Studies.

resultsThe pooled prevalence of MetS in PsA populations was 0.46 ± 0.06 (95% CI 0.40-0.51). In comparison, the prevalence of MetS in PsO and RA populations was 0.34 ± 0.03 (95% CI 0.32-0.37) and 0.31 ± 0.04 (95% CI 0.27-0.35), respectively. Patients with PsA were 1.62 ± 0.036 (95% CI 1.50-1.74) and 1.66 ± 0.038 (95% CI 1.54-1.79) times more likely to have MetS compared with PsO and RA populations.

conclusionThe prevalence of MetS is significantly increased in PsA populations compared with PsO and RA populations. Further studies should be performed using a standardized definition of MetS in PsA, RA, and PsO populations to determine whether addressing the metabolic components in MetS offers any therapeutic benefits and in terms of attaining MDA and improving cardiovascular health.

Indexed as

Arthritis, PsoriaticArthritis, RheumatoidFemaleHumansMaleMetabolic SyndromePrevalencePsoriasisRisk AssessmentRisk Factorscardiovascular riskmetabolic syndromepsoriasispsoriatic arthritisrheumatoid arthritis

Identifiers

PMID34076348
OpenAlexW3164267725

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.